Biological variation in fasting serum insulin-like growth factor binding protein-1 (IGFBP-1) among individuals with a varying glucose tolerance

Clinical Biochemistry

Volumn 42, Issue 12, 2009, Pages 1270-1274

  Borai, Anwar ^a   Livingstone, Callum ^a,b   Mehta, Shweta ^b   Zarif, Hawazen ^c   Abdelaal, Fatima ^c   Ferns, Gordon ^a,b  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^c KING KHALID NATIONAL GUARD HOSPITAL   (Saudi Arabia)

Author keywords

Biological variation; FPI; IGFBP 1; Reproducibility

Indexed keywords

GLUCOSE; INSULIN; SOMATOMEDIN BINDING PROTEIN 1;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DIET THERAPY; FEMALE; GENETIC VARIABILITY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RELIABILITY; REPRODUCIBILITY;

DIABETES MELLITUS, TYPE 2; FASTING; GLUCOSE INTOLERANCE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; REPRODUCIBILITY OF RESULTS;

EID: 67650735286     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.05.005     Document Type: Article

References (21)

1. Maddux B.A., Chan A., Mandarino L.J., and Goldfine I.D. IGF-binding protein-1 levels are related to insulin-mediated glucose disposal and are a potential serum marker of insulin resistance. Diabetes Care 29 (2006) 1535-1537
2. Borai A., Livingstone C., Zarif H., and Ferns G. Serum insulin-like growth factor binding protein-1: an improvement over other simple indices of insulin sensitivity in the assessment of subjects with normal glucose tolerance. Ann. Clin. Biochem. 49 (2009) 109-113
3. Brismar K., and Hall K. Clinical applications of IGFBP-1 and its regulation. Growth Regul. 3 (1993) 98-100
4. Jayagopal V., Kilpatrick E.S., Jennings P.E., Holding S., Hepburn D.A., and Atkin S.L. The biological variation of sex hormone-binding globulin in type 2 diabetes: implications for sex hormone-binding globulin as a surrogate marker of insulin resistance. Diabetes Care 27 (2004) 278-280
5. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15 (1998) 539-553
6. Raggatt P.R. Duplicates or singletons? An analysis of the need for replication in immunoassay and a computer program to calculate the distribution of outliers, error rate and the precision profile from assay duplicates. Ann. Clin. Biochem. 26 Pt 1 (1989) 26-37
7. Khosravi M.J., Diamandi A., and Mistry J. Immunoassay of insulin-like growth factor binding protein-1. Clin. Chem. 43 (1997) 523-532
8. Mooy J.M., Grootenhuis P.A., de Vries H., et al. Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia 39 (1996) 298-305
9. Heald A.H., Cruickshank J.K., Riste L.K., et al. Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia 44 (2001) 333-339
10. Wareham N.J., Byrne C.D., Williams R., Day N.E., and Hales C.N. Fasting proinsulin concentrations predict the development of type 2 diabetes. Diabetes Care 22 (1999) 262-270
11. Kotronen A., Vehkavaara S., Seppala-Lindroos A., Bergholm R., and Yki-Jarvinen H. Effect of liver fat on insulin clearance. Am. J. Physiol: Endocrinol. Metab. 293 (2007) E1709-E1715
12. Hilding A., Brismar K., Thoren M., and Hall K. Glucagon stimulates insulin-like growth factor binding protein-1 secretion in healthy subjects, patients with pituitary insufficiency, and patients with insulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 77 (1993) 1142-1147
13. Lang C.H., Nystrom G.J., and Frost R.A. Regulation of IGF binding protein-1 in hep G2 cells by cytokines and reactive oxygen species. Am. J. Physiol. 276 (1999) G719-G727
14. Lewitt M.S., Hilding A., Ostenson C.G., Efendic S., Brismar K., and Hall K. Insulin-like growth factor-binding protein-1 in the prediction and development of type 2 diabetes in middle-aged Swedish men. Diabetologia 51 (2008) 1135-1145
15. Jayagopal V., Kilpatrick E.S., Jennings P.E., Hepburn D.A., and Atkin S.L. Biological variation of homeostasis model assessment-derived insulin resistance in type 2 diabetes. Diabetes Care 25 (2002) 2022-2025
16. Borai A., Livingstone C., and Ferns G. The biochemical assessment of insulin resistance. Ann. Clin. Biochem. 44 (2007) 324-342
17. Lee P.D., Giudice L.C., Conover C.A., and Powell D.R. Insulin-like growth factor binding protein-1: recent findings and new directions. Proc. Soc. Exp. Biol. Med. 216 (1997) 319-357
18. Management of Diabetes Mellitus: Perspectives of Care Across the Life Span edited by Debra Haire-Joshu, MSEd, MSN, PhD, RN. Published by Mosby Year Book, 1992. ISBN 0-8016-2429-0.
19. Lewitt M.S., Denyer G.S., Cooney G.J., and Baxter R.C. Insulin-like growth factor-binding protein-1 modulates blood glucose levels. Endocrinology 129 (1991) 2254-2256
20. Hellman B., Gylfe E., Grapengiesser E., Dansk H., and Salehi A. Insulin oscillations-clinically important rhythm. Antidiabetics should increase the pulsative component of the insulin release. Lakartidningen 104 (2007) 2236-2239
21. Kroll M.H. Biological variation of glucose and insulin includes a deterministic chaotic component. Biosystems 50 (1999) 189-201